Literature DB >> 21876084

Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience.

Uday B Patel1, Fiona Taylor, Lennart Blomqvist, Christopher George, Hywel Evans, Paris Tekkis, Philip Quirke, David Sebag-Montefiore, Brendan Moran, Richard Heald, Ashley Guthrie, Nicola Bees, Ian Swift, Kjell Pennert, Gina Brown.   

Abstract

PURPOSE: To assess magnetic resonance imaging (MRI) and pathologic staging after neoadjuvant therapy for rectal cancer in a prospectively enrolled, multicenter study.
METHODS: In a prospective cohort study, 111 patients who had rectal cancer treated by neoadjuvant therapy were assessed for response by MRI and pathology staging by T, N and circumferential resection margin (CRM) status. Tumor regression grade (TRG) was also assessed by MRI. Overall survival (OS) was estimated by using the Kaplan-Meier product-limit method, and Cox proportional hazards models were used to determine associations between staging of good and poor responders on MRI or pathology and survival outcomes after controlling for patient characteristics.
RESULTS: On multivariate analysis, the MRI-assessed TRG (mrTRG) hazard ratios (HRs) were independently significant for survival (HR, 4.40; 95% CI, 1.65 to 11.7) and disease-free survival (DFS; HR, 3.28; 95% CI, 1.22 to 8.80). Five-year survival for poor mrTRG was 27% versus 72% (P = .001), and DFS for poor mrTRG was 31% versus 64% (P = .007). Preoperative MRI-predicted CRM independently predicted local recurrence (LR; HR, 4.25; 95% CI, 1.45 to 12.51). Five-year survival for poor post-treatment pathologic T stage (ypT) was 39% versus 76% (P = .001); DFS for the same was 38% versus 84% (P = .001); and LR for the same was 27% versus 6% (P = .018). The 5-year survival for involved pCRM was 30% versus 59% (P = .001); DFS, 28 versus 62% (P = .02); and LR, 56% versus 10% (P = .001). Pathology node status did not predict outcomes.
CONCLUSION: MRI assessment of TRG and CRM are imaging markers that predict survival outcomes for good and poor responders and provide an opportunity for the multidisciplinary team to offer additional treatment options before planning definitive surgery. Postoperative histopathology assessment of ypT and CRM but not post-treatment N status were important postsurgical predictors of outcome.

Entities:  

Mesh:

Year:  2011        PMID: 21876084     DOI: 10.1200/JCO.2011.34.9068

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  157 in total

Review 1.  [The role of cross-sectional imaging in staging of rectal cancer].

Authors:  A O Schäfer; M Langer; T Baumann
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

2.  T2 weighted signal intensity evolution may predict pathological complete response after treatment for rectal cancer.

Authors:  Ewelina Kluza; Esther D Rozeboom; Monique Maas; Milou Martens; Doenja M J Lambregts; Jos Slenter; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2012-07-10       Impact factor: 5.315

3.  Systematic review of prognostic importance of extramural venous invasion in rectal cancer.

Authors:  Manish Chand; Muhammed R S Siddiqui; Ian Swift; Gina Brown
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

4.  The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.

Authors:  Rob Glynne-Jones; Maher Hadaki; Mark Harrison
Journal:  J Gastrointest Oncol       Date:  2013-09

5.  T2-weighted signal intensity-selected volumetry for prediction of pathological complete response after preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Sungwon Kim; Kyunghwa Han; Nieun Seo; Hye Jin Kim; Myeong-Jin Kim; Woong Sub Koom; Joong Bae Ahn; Joon Seok Lim
Journal:  Eur Radiol       Date:  2018-06-01       Impact factor: 5.315

6.  The value of diffusion kurtosis magnetic resonance imaging for assessing treatment response of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  Jing Yu; Qing Xu; Jia-Cheng Song; Yan Li; Xin Dai; Dong-Ya Huang; Ling Zhang; Yang Li; Hai-Bin Shi
Journal:  Eur Radiol       Date:  2016-09-08       Impact factor: 5.315

7.  MRI can be used to assess advanced T-stage colon carcinoma as well as rectal carcinoma.

Authors:  Akitoshi Inoue; Shinichi Ohta; Norihisa Nitta; Masahiro Yoshimura; Tomoharu Shimizu; Masaji Tani; Ryoji Kushima; Kiyoshi Murata
Journal:  Jpn J Radiol       Date:  2016-10-18       Impact factor: 2.374

Review 8.  Advances and challenges in treatment of locally advanced rectal cancer.

Authors:  J Joshua Smith; Julio Garcia-Aguilar
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

9.  Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs.

Authors:  Christopher G Roth; Dina Halegoua-De Marzio; Flavius F Guglielmo
Journal:  Dig Dis Sci       Date:  2018-05       Impact factor: 3.199

10.  TNM staging of colorectal cancer should be reconsidered by T stage weighting.

Authors:  Jun Li; Bao-Cai Guo; Li-Rong Sun; Jian-Wei Wang; Xian-Hua Fu; Su-Zhan Zhang; Graeme Poston; Ke-Feng Ding
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.